Ocugen Inc (OCGN)
NASDAQ:OCGN
Top Page
Ocugen
(NASDAQ:OCGN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▲(6.95% Upside)
Action:ReiteratedDate:03/28/26
Overall score is held back primarily by weak financial performance (minimal revenue, sustained losses/cash burn, and negative equity), partially offset by a positive earnings-call outlook driven by pipeline progress and clearer regulatory timelines. Technicals are mixed but generally supportive over longer moving averages, while valuation support is limited due to ongoing losses and no dividend.
Positive Factors
Gene-agnostic Phase 3 program
OCU400's completed Phase 3 (Limelight) and a planned rolling BLA create a clear regulatory path for a gene-agnostic therapy that addresses >100 mutations. This durable clinical and regulatory progress reduces development uncertainty and positions Ocugen for broader market reach if approvals succeed.
Negative Factors
Negative shareholders' equity
Negative equity is a durable structural weakness that reduces financial flexibility, constrains collateral for financing, and can limit strategic options. For a clinical-stage biotech needing future funding, this increases the likelihood of dilutive financings or onerous financing terms over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Gene-agnostic Phase 3 program
OCU400's completed Phase 3 (Limelight) and a planned rolling BLA create a clear regulatory path for a gene-agnostic therapy that addresses >100 mutations. This durable clinical and regulatory progress reduces development uncertainty and positions Ocugen for broader market reach if approvals succeed.
Read all positive factors
Ocugen (OCGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$577.10M
Dividend YieldN/A
Average Volume (3M)10.44M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth14.26%
EPS Growth-23.34%
CountryUS
Employees95
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding327,897,300
10 Day Avg. Volume5,316,328
30 Day Avg. Volume10,443,310
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue134.07
Enterprise Value/Gross Profit134.07
Enterprise Value/Ebitda-9.78
Forecast
1Y Price Target
$12.33Price Target Upside559.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$1.67M
Ocugen Business Overview & Revenue Model
Company Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and f...
How the Company Makes Money
Ocugen has historically generated limited revenue because it is primarily a clinical-stage developer. When revenue occurs, it has generally come from: (1) collaboration/partnering arrangements (e.g., payments related to licensing, development, com...
Ocugen Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 01, 2026
Earnings Call Sentiment Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.Positive Updates
OCU400 Phase 3 Enrollment Complete
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
Negative Updates
Short Cash Runway and Financing Reliance
Reported cash and cash equivalents extend runway only into 2026 unless additional financing occurs. Ongoing reliance on potential $30.0M warrant exercises (uncertain) and licensing milestones to extend runway into 2027 introduces liquidity risk.
Read all updates
Q4-2025 Updates
Positive
Negative
OCU400 Phase 3 Enrollment Complete
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
Read all positive updates
Company Guidance
Management gave specific numerical guidance and timelines: OCU400 (Limelight) completed enrollment (n=140, randomized 2:1), uses a one‑year primary LDNA endpoint (clinically meaningful ≥1 lux), is on track to begin a rolling BLA in 2026 (Q3 cited), with top‑line data and potential approval/commercialization in 2027; OCU410 (GA) released preliminary 12‑month Phase 2 data showing a 46% lesion‑growth reduction versus control (p=0.015, cohort n=23), a 50% responder rate (>50% lesion reduction), subgroup ≥7.5 mm² with 56–57% reductions, and a Phase‑1 observation of 60% slower EZ loss, with full Phase 2 data due this month and Phase 3 planned in 2026; OCU410ST (Stargardt) is ahead of schedule with enrollment expected complete in early‑2026, an adaptive masked interim analysis of 24 subjects (16 treatment/8 control) planned in Q3 and top‑line Phase 2/3 data and a BLA path targeted in 2027, with EZ exploratory results showing ~16% lesion reduction and 50% of treated eyes achieving EZ preservation at 12 months; other programs: OCU200 enrollment expected complete in 2026 and OCU500 Phase‑1 initiation by NIAID in 2026; and financial guidance: FY2025 R&D $39.8M (Q4 $10.7M), G&A $27.6M (Q4 $6.1M), FY2025 net loss per share $0.23 (Q4 $0.06), cash runway into 2026 supported by a $22.5M registered direct raise and a potential extension into 2027 if $30M of warrants are fully exercised, with management reiterating a plan to file three BLAs in the next three years.Ocugen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.41M | 4.05M | 6.04M | 2.49M | 0.00 |
| Gross Profit | 2.02M | 2.09M | 5.33M | 2.49M | 0.00 |
| EBITDA | -60.53M | -52.79M | -64.83M | -88.59M | -57.80M |
| Net Income | -67.85M | -54.05M | -63.08M | -86.80M | -58.37M |
Balance Sheet | |||||
| Total Assets | 43.52M | 82.44M | 64.55M | 108.63M | 105.76M |
| Cash, Cash Equivalents and Short-Term Investments | 18.57M | 58.51M | 39.46M | 90.93M | 94.96M |
| Total Debt | 33.14M | 32.50M | 6.94M | 6.37M | 3.31M |
| Total Liabilities | 56.45M | 52.81M | 23.98M | 34.65M | 9.94M |
| Stockholders Equity | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M |
Cash Flow | |||||
| Free Cash Flow | -57.15M | -45.53M | -72.53M | -64.54M | -48.88M |
| Operating Cash Flow | -56.96M | -42.14M | -62.05M | -60.08M | -47.94M |
| Investing Cash Flow | -311.00K | -3.38M | 3.08M | -16.97M | -1.82M |
| Financing Cash Flow | 17.33M | 64.86M | 20.88M | 59.48M | 120.68M |
Ocugen Technical Analysis
Negative
1.87
Price Trends
1.78
Negative
1.59
Positive
1.42
Positive
Market Momentum
-0.03
Positive
44.52
Neutral
48.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCGN, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 1.99, above the 50-day MA of 1.78, and above the 200-day MA of 1.42, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 44.52 is Neutral, neither overbought nor oversold. The STOCH value of 48.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OCGN.
Ocugen Risk Analysis
Ocugen disclosed 6 risk factors in its most recent earnings report. Ocugen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ocugen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $437.41M | 15.08 | 16.22% | ― | 118.02% | ― | |
56 Neutral | $456.00M | -4.14 | -59.68% | ― | -33.09% | 3.38% | |
54 Neutral | $1.44B | ― | -15.12% | ― | 1112.27% | ― | |
52 Neutral | $577.10M | ― | -2626.38% | ― | 14.26% | -23.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $460.27M | ― | ― | 0.00% | ― | ― | |
47 Neutral | $475.15M | -3.14 | 76.03% | ― | 6.35% | 39.57% |
* Healthcare Sector Average
OCGN
Ocugen
1.76
1.07
155.07%
SVA
Sinovac Biotech
6.47
0.00
0.00%
XOMA
XOMA Royalty Corporation
36.74
16.77
83.98%
ADCT
ADC Therapeutics
3.74
2.52
206.56%
GLUE
Monte Rosa Therapeutics
17.48
13.26
314.22%
ABSI
AbSci
2.98
-0.04
-1.32%
Ocugen Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies
Positive
Mar 27, 2026
Ocugen has updated its corporate presentation as of March 2026, outlining an aggressive clinical and regulatory roadmap targeting three Biologics License Application submissions in three years for its lead ophthalmic gene therapy candidates. The c...
Business Operations and StrategyProduct-Related Announcements
Ocugen Reports Positive Phase 2 Data for OCU410 Therapy
Positive
Mar 24, 2026
On March 24, 2026, Ocugen reported positive 12‑month topline data from its Phase 2 ArMaDa trial of OCU410, a one-time AAV5-based modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The study showed...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Gains $15 Million, Extends Cash Runway to 2027
Positive
Mar 20, 2026
In August 2025, Ocugen, Inc. completed a registered direct offering with an institutional investor involving 20,000,000 shares of common stock and warrants to purchase up to an additional 20,000,000 shares, reinforcing its equity-based funding str...
Legal ProceedingsRegulatory Filings and ComplianceShareholder Meetings
Ocugen Seeks Court Validation of Charter Amendment Dispute
Negative
Mar 4, 2026
On June 28, 2024, Ocugen’s shareholders voted on a proposal to increase authorized common shares from 295 million to 390 million, and the company subsequently filed a charter amendment on July 10, 2024, after treating the vote as valid based...
Executive/Board Changes
Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer
Positive
Feb 9, 2026
On February 9, 2026, Ocugen, Inc. appointed Rita Johnson-Greene as its Chief Financial Officer, with her role as principal financial officer to begin after the filing of the company’s annual report for the year ended December 31, 2025. Johns...
Business Operations and StrategyPrivate Placements and Financing
Ocugen strengthens balance sheet with new equity financing
Positive
Jan 23, 2026
On January 22–23, 2026, Ocugen, Inc. closed an underwritten registered direct offering of 15,000,000 shares of common stock at $1.50 per share, raising $22.5 million in gross proceeds and approximately $20.85 million in net proceeds after co...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Announces $22.5 Million Public Stock Offering
Positive
Jan 21, 2026
On January 20, 2026, Ocugen, Inc. entered into an underwriting agreement with Oppenheimer Co. Inc. for an underwritten public offering of 15 million shares of its common stock at $1.50 per share, raising gross proceeds of $22.5 million and an exp...
Business Operations and StrategyProduct-Related Announcements
Ocugen Reports Encouraging 12-Month Data for OCU410
Positive
Jan 15, 2026
On January 15, 2026, Ocugen reported positive preliminary 12‑month data from its Phase 1 and Phase 2 ArMaDa trials of OCU410, an AAV5-based modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, a con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.